Umbilical Cord Stem Cell Therapy , livre ebook

Turner Publishing Company - Anthony G. Payne , David A. Steenblock

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris

Obtenez un accès à la bibliothèque pour le consulter en ligne
En savoir plus

116 pages

English

Vous pourrez modifier la taille du texte de cet ouvrage

Obtenez un accès à la bibliothèque pour le consulter en ligne
En savoir plus

A propos
Informations
Extrait

Description

The debate over the use of Embryonic stem cells and the questionable effectiveness of adult stem cells have led many scientists and clinicians to concentrate their energies on umbilical-cord-derived stem cells from healthy newborn babies. Amassing a very respectable track record in terms of safety and clinical utility, cord-blood stem cells can treat many diseases such as multiple sclerosis, amyotrophic lateral sclerosis, stroke, diabetes, heart disease and certain degenerative eye disorders.

Sujets

Embryonic stem cell

Healing

Health

Fitness

Informations

Publié par	Turner Publishing Company
Date de parution	15 mars 2006
Nombre de lectures	0
EAN13	9781591205876
Langue	English

Informations légales : prix de location à la page 0,0598€. Cette information est donnée uniquement à titre indicatif conformément à la législation en vigueur.

Extrait

Umbilical
Cord
Stem Cell
Therapy
Umbilical
Cord
Stem Cell
Therapy
The Gift of Healing from Healthy Newborns
DAVID A. STEENBLOCK, M.S., D.O., AND ANTHONY G. PAYNE, PH.D.
The information contained in this book is based upon the research and personal and professional experiences of the authors. It is not intended as a substitute for consulting with your physician or other healthcare provider. Any attempt to diagnose and treat an illness should be done under the direction of a healthcare professional.
The publisher does not advocate the use of any particular healthcare protocol but believes the information in this book should be available to the public. The publisher and authors are not responsible for any adverse effects or consequences resulting from the use of the suggestions, preparations, or procedures discussed in this book. Should the reader have any questions concerning the appropriateness of any procedures or preparation mentioned, the authors and the publisher strongly suggest consulting a professional healthcare advisor.
Basic Health Publications, Inc.
28812 Top of the World Drive
Laguna Beach, CA 92651
949-715-7327
Library of Congress Cataloging-in-Publication Data
Steenblock, David.
Umbilical-cord stem-cell therapy : the gift of healing from healthy newborns / David Steenblock and Anthony G. Payne.
   p. cm.
Includes bibliographical references and index.
ISBN-13: 978-1-59120-587-6
ISBN-10: 1-59120-125-X
1. Fetal blood—Transplantation. 2. Hematopoietic stem cells—Transplantation. 3. Cellular therapy. 4. Gene therapy. I. Payne, Anthony G. II. Title.
RM171.4.S69    2006
616’.02774—dc22
2005032200
Copyright © 2006 by David A. Steenblock, M.S., D.O., and Anthony G. Payne, Ph.D.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the copyright owner.
Editor: Carol Rosenberg
Typesetting/Book design: Gary A. Rosenberg
Cover design: Mike Stromberg
Printed in the United States of America
10    9    8    7    6    5    4    3    2    1
C ontents
Acknowledgments
Authors’ Note
Introduction: A Brief History of Stem-Cell Therapy
1.   Stem Cells: The Body–s Repair Kit
2.   Umbilical-Cord-Derived Stem Cells
3.   Improving the Response to Umbilical-CordStem-Cell Therapy
4.   Case Histories
Multiple Sclerosis
Cerebral Palsy
Diseases of the Eyes
Stroke
Amyotrophic Lateral Sclerosis (ALS)
Traumatic Brain Injury
5.   Questions and Answers on Umbilical-CordStem-Cell Therapy
6.   Dietary Considerations Following Stem-Cell Therapy
7.   Natural Methods of Stem-Cell Renewal
Conclusion: The Road to Improvement for Many
Glossary
Appendix A: Ethics and Politics of Stem-Cell Therapy
Appendix B: Battlefield Traumatic Brain Injury
Resources
Selected References and Notes
About Steenblock Research Institute (SRI)
About the Authors
With love and appreciation to my wife, Noyemy daughters, Karen and Amber; and my son, David Jr. (who is proudly serving his country in the U.S. Army in Iraq), for their support, encouragement, and sacrifices in all my endeavors down through the years including the writing of this book.
I also extend heartfelt thanks to all the researchers, physicians, therapists, and scores of patients who have helped transform vision into reality, and theory into milestones of progress for the betterment of the human condition.
—D AVID A. S TEENBLOCK , M.S., D.O.
Dedicated to the pioneers—those stalwart souls who have chosen to step into the vast undiscovered frontier, to resist fear and persevere against all obstacles, and by doing so to move themselves and all of us ever forward.
Among them: my wife, Sachi Tsujii-Payne; my fellow traveler along the road of discovery, Dr. David Steenblock; Dr. Fernando Ramirez of the Spinal Cord Regeneration Center in Tijuana, Mexico; Steenblock Research Institute’s (SRI’s) research assistant, Lyn Darnall; chemist Marie Colucci; lab tech Sue Hardin; biomedical engineer Kevork DerAlexanian; medical librarian Karen Sullins; volunteer E/S translator Grace Odgers; and the more than one hundred patients and parents and caregivers of patients who took an informed step into the land of promise, which is human umbilical-cord stem-cell therapy.
—A NTHONY G. P AYNE , P H .D.
Acknowledgments
The authors wish to extend heartfelt thanks to the following people whose direct or indirect input influenced the evolution and content of this book:
Fernando Ramirez, M.D., Director of the Spinal Cord Regeneration Center, Tijuana, Mexico; Paul Sanberg, Ph.D., D.Sc., Distinguished University Professor, Director of the Center of Excellence for Aging and Brain Repair, and Associate VP/Associate Dean for Biotechnology Development at the University of South Florida College of Medicine; Kathy Mitchell, Ph.D., Associate Professor, Department of Pharmacology & Toxicology at the University of Kansas–Laurence; Norman Ende, M.D., of UMD–New Jersey Medical School; Lyn Darnall, M.A., M.Ed., statistician and senior science writer for Steenblock Research Institute; Dave Bloom, President of Bloom Public Relations ( www.ournewsroom.com ); Sheri Schultz, Ph.D., at Albert Einstein College of Medicine, NYC; Larry Howard, President of Weller Health Institute ( www.wellerhealthinstitute.com ); and Emer Clarke, Ph.D., at Stem-cell Technologies, Inc. ( www.stemcell.com ).
Authors’ Note
We are standing at the threshold of a new and exciting medical era—an era of regeneration, rejuvenation, and renewal in which stem cells will set the stage for healing and, in some cases, the restoration of injured, diseased, and debilitated tissues and organs. However, it would be premature to portray this emerging field as “miraculous” or “magical.” Stem-cell therapy is surely in its infancy, but it is rich with promise. And though it is buttressed by a tremendous body of scientific work, the therapeutic administration of stem cells is often empiric—meaning that there is often a lot of “give and watch” and “tweak and try again” (more commonly known as “trial and error”). This is a familiar and recurring theme in medicine.
In the pages that follow, we share some of the science that underlies stem-cell therapy and put a human face on this field with accounts of people who have benefited from human umbilical-cord stem-cell treatments. And, in providing this information, we encourage you, the reader, to take that bold first step into this vast and wondrous new medical frontier.
… science proceeds as a series of successive approximations.
–EDWIN POWELL HUBBLE IN THE NATURE OF SCIENCE AND OTHER LECTURES , 1954
INTRODUCTION

A Brief History of Stem-Cell Therapy
T he first recorded medical use of stem cells occurred about a century ago when doctors administered stem-cell-rich bone marrow by mouth to patients with anemia or leukemia. Although this attempt to cure or improve these conditions failed, scientists eventually were able to demonstrate that mice with defective bone marrow could be restored to robust health when injected with marrow taken from healthy mice. Quite naturally, this suggested that bone marrow could be transplanted from one human to another.
This process, known as “allogeneic transplantation,” was attempted for the first time in people in the late 1950s in France. Patients with leukemia were given doses of radiation that wiped out their marrow, and this was followed by bone-marrow infusions. In many cases, their bodies made new marrow and began producing white and red blood cells, but all of the patients eventually died due to infections or a return of their cancer. All in all, almost 200 allogenic bone-marrow transplants were performed from the late 1950s through the 1960s, but without long-term success. However, transplantation involving identical-twin donors was fairly successful and thus served as a foundation for continued clinical research.
Getting a recipient’s body to accept and utilize donated bone marrow was an obvious challenge. In 1958, French scientist Jean Dausset identified the reason for rejection. He found that specialized proteins exist on the surface of the majority of cells in an individual’s body, marking the cells and tissues they make up as unique to the individual. These surface markers were dubbed “human leukocyte antigens” (HLA antigens) or “human histocompatibility antigens.” It is these markers that make it possible for the immune system to determine what belongs and what doesn’t belong in an individual’s body. When the immune system encounters foreign markers, or antigens, on a cell, it generates antibodies and other substances to destroy what it perceives as an invader. Disease-causing bacteria, viruses, cancer cells, and foreign matter that breeches the skin are among the “invaders” that the immune system is designed to detect and eradicate.
This surveillance system helps defend the body against things that can cause it harm. This protective mechanism, however, is also behind a recipient’s rejection of bone marrow, which carries surface markers that say, “foreign to the body.” Therefore, it follows that the antigens on the donated bone marrow must closely match that of the recipient for a bone marrow transplant to take hold. Naturally, bone-marrow transplants between identical twins ensure a 100-percent match between donor and recipient. (Such transplants were among the first to be systematically performed in people.) In the 1960s, as physicians and researchers became more adept at determining HLA compatibility, they began to carry out successful bone-marrow transplants between siblings who were not identical twins.
In 1973, doctors at Memorial Sloan-Kettering Cancer Center in New York City performed the first bone-marrow transplant in which marrow from an unrelated donor was given to a five-year-old child with severe comb